Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter N Morcos

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Hepatology (Baltimore, Md.)|May 30, 2008
A grapefruit a day for patients infected with hepatitis C?Peter N Morcos, Barbara Brennan, Patrick F Smith
Expert Review of Clinical Pharmacology|March 12, 2013
Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritisXiaoping Zhang, Peter N Morcos, Tomohisa Saito, et al.
Clinical and Translational Science|September 4, 2020
Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and OpportunitiesPeter N Morcos, Junyi Li, Iraj Hosseini, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2019
Rituximab dosing in hematological malignancies: an old question, revisitedPeter N Morcos, Axel Boehnke, Nancy Valente, et al.
Clinical Pharmacology and Therapeutics|February 7, 2019
Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung CancerPeter N Morcos, Jiang Liu, Gideon M Blumenthal, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2020
Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugsWenying Angela Liu, Li Yu, Peter N Morcos, et al.
Bioanalysis|February 9, 2017
LC-MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific bindingKatja Heinig, Denis Herzog, Luca Ferrari, et al.
The AAPS Journal|July 25, 2016
Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of AlectinibNeil J Parrott, Li J Yu, Ryusuke Takano, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 4, 2013
Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20Peter N Morcos, Xiaoping Zhang, Christine McIntyre, et al.
Clinical Pharmacology and Therapeutics|January 16, 2024
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing RegimenPeter N Morcos, Jonathan Moss, Josh Veasy, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Hepatology (Baltimore, Md.)|May 30, 2008
A grapefruit a day for patients infected with hepatitis C?Peter N Morcos, Barbara Brennan, Patrick F Smith
Expert Review of Clinical Pharmacology|March 12, 2013
Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritisXiaoping Zhang, Peter N Morcos, Tomohisa Saito, et al.
Clinical and Translational Science|September 4, 2020
Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and OpportunitiesPeter N Morcos, Junyi Li, Iraj Hosseini, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2019
Rituximab dosing in hematological malignancies: an old question, revisitedPeter N Morcos, Axel Boehnke, Nancy Valente, et al.
Clinical Pharmacology and Therapeutics|February 7, 2019
Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung CancerPeter N Morcos, Jiang Liu, Gideon M Blumenthal, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2020
Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugsWenying Angela Liu, Li Yu, Peter N Morcos, et al.
Bioanalysis|February 9, 2017
LC-MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific bindingKatja Heinig, Denis Herzog, Luca Ferrari, et al.
The AAPS Journal|July 25, 2016
Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of AlectinibNeil J Parrott, Li J Yu, Ryusuke Takano, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 4, 2013
Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20Peter N Morcos, Xiaoping Zhang, Christine McIntyre, et al.
Clinical Pharmacology and Therapeutics|January 16, 2024
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing RegimenPeter N Morcos, Jonathan Moss, Josh Veasy, et al.
Pageof 6